June 03, 2024
Live From MarketSite: Cellares CEO and Co-Founder, Fabian Gerlinghaus Interviewed by Nasdaq Listings Host Kristina Ayanian on Cellares’ $380M Worldwide Capacity Reservation and Supply Agreement with Bristol Myers Squibb
Related News
-
April 10, 2025Cellares and University of Wisconsin School of Medicine and Public Health to Automate Clinical-Scale Production of CRISPR-Edited CAR-T for Solid Tumors
-
April 01, 2025
Cellares’ Cell Shuttle Receives FDA Advanced Manufacturing Technology (AMT) Designation for Automated Cell Therapy Manufacturing
-
March 19, 2025
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform
